Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07132112) titled 'GT719 Injection for Moderate to Severe Refractory Autoimmune Disease' on Aug. 14.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Grit Biotechnology

Condition: Auto Immune Disease

Intervention: Biological: GT719 Injection

Recruitment Status: Not recruiting

Phase: Early Phase 1

Date of First Enrollment: August 2025

Target Sample Size: 30

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07132112

Published by HT Digital Content Services...